Drug Profile
Research programme: miRNA therapeutics - Synlogic
Alternative Names: let-7; let-7 mimic; let-7b; let-7c; let-7g; miR-101; miR-192; miR-215; miR-Rx01; miR-Rx02; miR-Rx03; miR-Rx04; miR-Rx05; miR-Rx06; miR-Rx07; miR-Rx16; miR-Rx16 mimic; miR-Rxlet-7; Tumour suppressor microRNAs - SynlogicLatest Information Update: 08 Apr 2021
Price :
$50
*
At a glance
- Originator Asuragen
- Developer Mirna Therapeutics; Synlogic; University of Texas M. D. Anderson Cancer Center
- Class MicroRNAs
- Mechanism of Action Oncogene protein inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bladder cancer; Colorectal cancer; Gastric cancer; Haematological malignancies; Liver cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer
Most Recent Events
- 06 Apr 2021 Asuragen has been acquired by Bio-Techne
- 28 Apr 2020 No recent reports of development identified for preclinical development in Bladder-cancer in USA
- 28 Apr 2020 No recent reports of development identified for preclinical development in Gastric-cancer in USA